Background
Study (et al.) | Year | Gene | Type | Population | Results |
---|---|---|---|---|---|
Danesh [17] | 2018 | miR-218-2, miR-301b | Sporadic | 288 Controls 266 Patients | Polymorphism was correlated with BC risk |
Heydari [19] | 2018 | mir-140-3p | Sporadic | 40 Controls 40 Patients | Over expression |
Parchami Barjui [20] | 2017 | miR-502 | Sporadic | 231 Controls 240 Patients | Polymorphism was correlated with BC risk |
Omrani [21] | 2014 | hsa-miR-499 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
Hashemi [23] | 2016 | mir-608 | Sporadic | 192 Controls 160 Patients | Polymorphism was correlated with BC risk |
Savad [26] | 2012 | miR-342 | Sporadic | 77 N/Ta | Over expression in ER/PR positive tumors |
Mansoori [28] | 2016 | miR34a, let-7a | Sporadic | 45 N/T | Under expression |
Saberi [29] | 2016 | miR-328 | Sporadic | 28 N/T | Over expression |
Damavandi [30] | 2016 | miR-132, miR-212, and miR-22 | Sporadic | 36 N/T | Correlation with grade and stage |
Nejati-Azar [32] | 2018 | miR-196a | Sporadic | 200 Controls 200 Patients | Polymorphism was correlated with BC risk |
Sarrafzadeh [35] | 2017 | CCAT2 | Familial/ Sporadicb | 48 N/T | Correlation with stage an lymph node metastasis |
Hassanzarei [37] | 2017 | HOTAIR | Sporadic | 231 Controls 220 Patients | Polymorphism was correlated with BC risk |
Miri [42] | 2012 | eRF3a/GSPT1 | Familial/ Sporadic | 250 Controls 250 Patients | Polymorphism was correlated with BC risk |
Hosseini [45] | 2011 | MTHFR | Sporadic | 306 Controls 294 Patients | Polymorphism was correlated with BC risk |
Rezaei [46] | 2017 | MTHFR | Familial/ Sporadic | 84 Patients | Polymorphism was correlated with BC risk |
Jahangiri [48] | 2018 | DNMT1, DNMT3A, and DNMT3B | Sporadic | 72 Patients | Correlation with grade |
Eftekhar [49] | 2014 | DNMT3B | Sporadic | 138 Controls 100 Patients | Polymorphism was correlated with BC risk |
Hashemi [51] | 2012 | CASP8 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
Aghababazadeh [52] | 2017 | CASP8 | Familial/ Sporadic | 27 N/T | Under expression |
Eskandari-Nasab [54] | 2015 | TP53 | Sporadic | 203 Controls 236 Patients | Polymorphism was correlated with BC risk |
Payandeh [55] | 2016 | P53 | Sporadic | 231 Patients | Correlation with grade and lymph node metastasis |
Rostamizadeh [58] | 2013 | BCL-2 | Sporadic | 40 Patients | Correlation with grade and survival |
Golmohammadi [61] | 2016 | PTEN | Sporadic | 100 Patients | Correlation with stage and survival |
Sadeq [62] | 2011 | PTEN | Sporadic | 20 Controls 57 Patients | Hypermethylation was correlated with stage and lymph node metastasis |
Yari [63] | 2016 | PTEN | Familial/ Sporadic | 50 Controls 103 Patients | Methylation |
Ghaffari [64] | 2016 | BIRC5 | Sporadic | 40 Patients | Correlation with age |
Vallian [70] | 2009 | p16INK4A | Sporadic | 70 Controls 70 Patients | Methylation was correlated with stage |
Salimi [72] | 2012 | ATM and cyclinD1 | Sporadic | 119 Patients | ATM under expression and cyclinD1 over expression |
Mehdipour [73] | 2011 | ATM | Sporadic | 248 Controls 129 Patients | Polymorphism was correlated with BC risk |
Amininia [75] | 2014 | CCNE1 | Sporadic | 225 Controls 266 Patients | Polymorphism was correlated with BC risk |
Hajikhan Mirzaei [78] | 2012 | DBC2 | Sporadic | 50 Patients | Methylation |
Golmohammadi [79] | 2017 | AURKA | Sporadic | 100 Controls 100 Patients | Polymorphism was correlated with BC risk |
Mojgan [80] | 2012 | ERCC1 | Sporadic | 126 Controls 300 Patients | Polymorphism was correlated with BC risk |
Jalali [83] | 2016 | XRCC1 | Sporadic | 200 Controls 100 Patients | Polymorphism was correlated with BC risk |
Rezaei [86] | 2016 | FEN1 | Sporadic | 225 Controls 266 Patients | Mutation |
Madjd [88] | 2014 | EMSY | Familial/ Sporadic | 116 Patients | Correlation with tumor size and lymph node metastasis |
Hallajian [91] | 2017 | ATM, RAD51, and BRCA1 | Sporadic | 50 Patients | Under expression |
Darbeheshti [94] | 2018 | BRCA1 | Sporadic | 53 Patients | Correlation with grade and lymph node metastasis |
Madjd [95] | 2011 | BRCA1 | Familial/ Sporadic | 156 Patients | Correlation with grade |
Rezaei [96] | 2015 | APOBEC3 | Sporadic | 217 Controls 262 Patients | Mutation |
Abbasi [98] | 2017 | FANCA | Familial/ Sporadic | 295 Controls 304 Patients | Mutation |
Hashemi [102] | 2014 | hTERT | Sporadic | 225 Controls 266 Patients | Polymorphism was correlated with BC risk |
Haghi [108] | 2015 | HLA-G | Sporadic | 255 Controls 227 Patients | Polymorphism was correlated with BC risk |
Mahmoodi [109] | 2012 | HLA-II | Sporadic | 80 Controls 100 Patients | Polymorphism was correlated with BC risk |
Ghaderi [110] | 2001 | HLADRB1 | Sporadic | 36 Controls 36 Patients | Polymorphism was correlated with BC risk |
Faghih [113] | 2009 | IL13 | Sporadic | 195 Controls 305 Patients | Polymorphism was correlated with BC risk |
Khodadadi [119] | 2014 | IL-27 and IL-23 | Sporadic | 50 Controls 50 Patients | Over expression |
Vahedi [120] | 2018 | CCR7 | Sporadic | 70 N/T | Correlation with stage, grade, and lymph node metastasis |
Jafarzadeh [123] | 2015 | CCL22 | Sporadic | 100 Controls 100 Patients | Correlation with stage |
Dayer [124] | 2018 | CXCR4 | Sporadic | 36 N/T | Over expression in HER2 positive tumors |
Jaberipour [127] | 2010 | FOXP3 and CTLA-4 | Sporadic | 40 Controls 55 Patients | Correlation with stage and grade |
Hamidinia [128] | 2013 | FOXP3 and OX40 | Sporadic | 40 Controls 40 Patients | Correlation with stage |
Rostami [134] | 2015 | Leptin | Sporadic | 171 Controls 203 Patients | Polymorphism was correlated with BC risk |
Mohammadzadeh [136] | 2015 | Leptin | Sporadic | 100 Controls 100 Patients | Polymorphism was correlated with BC risk |
Pornour [140] | 2014 | DRD2, DRD4 | Sporadic | 30 Controls 30 Patients | Over expression |
Amani [141] | 2014 | TGFβ1 | Sporadic | 110 Controls 110 Patients | Polymorphism was correlated with BC risk |
Parvizi [142] | 2016 | TGF-β | Sporadic | 100 Controls 100 Patients | Polymorphism was correlated with BC risk |
Tabatabaeian [143] | 2013 | HER-2 | Familial/sporadic | 15 Controls 80 Patients | Over expression |
Panahi [144] | 2013 | HER-2 | Familial | 299 Patients | Correlation with ER/PR |
Amirifard [145] | 2016 | HER-2 | Familial/sporadic | 130 Patients | Correlation with stage and age |
Salimi [146] | 2016 | ERBB4 | Familial/sporadic | 192 Controls 172 Patients | Polymorphism was correlated with BC risk |
Mansouri Bidkani [147] | 2018 | ERBB4 | Familial/sporadic | 148 Controls 172 Patients | Polymorphism was correlated with BC risk |
Bagheri [148] | 2016 | ERBB4 | Sporadic | 146 Controls 146 Patients | Polymorphism was correlated with BC risk |
Eskandari-Nasab [152] | 2012 | NGX6 | Sporadic | 203 Controls 236 Patients | Under expression |
Seifi-Alan [154] | 2018 | NRP1 | Sporadic | 48 N/T | Correlation with stage, grade, and lymph node metastasis |
Javadi [156] | 2012 | IGF-1 | Familial/sporadic | 224 Controls 215 Patients | Mutation |
Azizi Tabesh [158] | 2017 | PIK3CA | Sporadic | 80 Patients | Mutation |
Sanaei [159] | 2017 | KRAS | Sporadic | 204 Controls 244 Patients | Polymorphism was correlated with BC risk |
Nazouri [160] | 2017 | SPHK1 | Sporadic | 120 Patients | Correlation with BMI |
Heshmatpour [164] | 2014 | PIK3CA | Sporadic | 200 Controls 200 Patients | Polymorphism was correlated with BC risk |
Ghalaei [165] | 2018 | APPL2 and OCC1 | Sporadic | 30 N/T | APPL2 under expression and OCC1 over expression |
Karami-Tehrani [166] | 2016 | RIP1K and RIP3K | Sporadic | 20 Normal 45 Tumor | Correlation with grade |
Nikseresht [168] | 2010 | UBE2Q2 | Sporadic | 21 N/T | Over expression |
Hashemi [170] | 2012 | GSTM1, GSTT1, GSTP1 | Sporadic | 152 CONTROLS 134 PATIENTS | Polymorphism was correlated with BC risk |
Sharif [171] | 2017 | GSTO1, GSTO2 | Sporadic | 150 Controls 153 Patients | Polymorphism was correlated with BC risk |
Saadatian [173] | 2014 | CYP1A1 | Sporadic | 100 Controls 100 Patients | Polymorphism was correlated with BC risk |
Saghafi [174] | 2018 | CYP2D6 | Familial/ Sporadic | 84 Patients | Polymorphism was correlated with BC risk |
Yazdi [179] | 2015 | CYP2D6 | Sporadic | 101 Patients | Polymorphism was correlated with BC risk |
Homaei-Shandiz [184] | 2016 | HSP27 | Sporadic | 65 Controls 97 Patients | High levels of serum anti Hsp27 |
Ghafouri [187] | 2016 | ABCG2 | Sporadic | 200 Controls 100 Patients | Polymorphism was correlated with BC risk |
Estiar [189] | 2017 | CEACAM19 | Sporadic | 75 Patients | Over expression |
Moazzezy [192] | 2014 | CA15-3 and CEA | Sporadic | 30 Controls 30 Patients | Over expression |
Mansouri [193] | 2016 | MUC1 | Sporadic | 50 Patients | Over expression |
Zarei [196] | 2017 | CDH1 | Sporadic | 200 Controls 100 Patients | Polymorphism was correlated with BC risk |
Esmaeili [198] | 2018 | CD44 | Familial/ Sporadic | 175 Controls 175 Patients | Polymorphism was correlated with BC risk |
Sadeghi [202] | 2017 | EpCAM | Sporadic | 122 Patients | Correlation with grade |
Taghizadeh-Kermani [204] | 2014 | CD10 | Sporadic | 150 Patients | Correlation with grade, lymph node metastasis, and tumor size |
Fard [207] | 2018 | CAV-1 | Sporadic | 203 Controls 203 Patients | Polymorphism was correlated with BC risk |
Mobasheri [208] | 2016 | SYCP3 | Sporadic | 47 Patients | Over expression |
Malek-Hosseini [209] | 2017 | SDC1 | Familial/ Sporadic | 30 Controls 61 Patients | Correlation with tumor size |
Karami-Tehrani [213] | 2012 | PDE5 and PDE9 | Sporadic | 70 N/T | Correlation with stage, grade, and lymph node metastasis |
Karami-Tehrani [215] | 2012 | PKG | Sporadic | 70 N/T | Under expression |
Paryan [218] | 2016 | NOTCH1 | Sporadic | 20 N/T | Correlation with tumor type |
Taghavi [220] | 2016 | WISP1 | Familial/ Sporadic | 15 Controls 85 Patients | Correlation with age and tumor size |
Madjd [224] | 2012 | ALDH1 | Familial/ Sporadic | 127 Patients | Correlation with BRCA1 |
Jahangiri [229] | 2018 | PAX2 | Sporadic | 72 Patients | Correlation with survival |
Estiar [233] | 2017 | NDRG3 | Sporadic | 6 Normal 88 Tumor | Correlation with survival |
Hosseini [234] | 2014 | ERα | Sporadic | 10 Normal 19 Tumor | Over expression |
Abbasi [235] | 2013 | ERα | Familial/ Sporadic | 147 Controls 150 Patients | mutation |
Farzaneh [236] | 2016 | CYP19 | Sporadic | 135 Controls 134 Patients | Polymorphism was correlated with BC risk |
Kamali-Sarvestani [241] | 2005 | TNF-α | Sporadic | 160 Patients | Polymorphism was correlated with BC risk |
Vakil Monfared [245] | 2018 | TNFSF4 | Sporadic | 126 Controls 123 Patients | Polymorphism was correlated with BC risk |
Colagar [250] | 2015 | VDR | Sporadic | 127 Controls 134 Patients | Microsatellite |
Zhalehjoo [255] | 2017 | CYP24A1 and CYP27B1 | Sporadic | 30 N/T | Correlation with stage and age |
Shahabi [256] | 2018 | VDR | Familial/ Sporadic | 214 Controls 203 Patients | Polymorphism was correlated with BC risk |
Shahbazi [257] | 2013 | VDR | Sporadic | 156 Controls 140 Patients | Polymorphism was correlated with BC risk |
Ebrahimi [260] | 2017 | CYP17 | Familial/ Sporadic | 205 Patients | Polymorphism was correlated with BC risk |
Esmaeili [263] | 2015 | AKAP3 | Sporadic | 162 N/T | Correlation with stage and tumor size |
Nourashrafeddin [266] | 2015 | WBP2NL | Sporadic | 30 Normal 50 Tumor | Over expression |
Rastgoosalami [267] | 2016 | MAGE-1 | Sporadic | 113 Patients | Correlation with lymph node metastasis and tumor size |
Dianatpour [268] | 2012 | TSGA10 | Sporadic | 50 Patients | Expression |
Kazemi-Oula [272] | 2015 | ODF4 and RHOXF2 | Familial/Sporadic | 40 N/T | Over expression |
Arezi [278] | 2018 | ND4 | Sporadic | 28 Normal 60 Tumor | Mutation |
Ghaffarpour [282] | 2014 | ATPase6 | Sporadic | 49 Patients | Mutation |
Main text
Non coding RNAs and epigenetic modifications
Apoptosis, DNA repair, and cell cycle
Immune response
Kinases and growth factors
Intracellular defense systems and drug resistance
Cell adhesion, cytoskeletal factors, and ECM
Cell signaling and self renewal
Vitamin D and steroids
Cancer testis antigens
Mitochondrial DNA
Conclusions
Gene | Number of studies | Number of patients (total) | Number of controls (total) |
---|---|---|---|
CYP2D6 | 2 | 185 | – |
FOXP3 | 2 | 95 | 80 |
LEPTIN | 2 | 303 | 271 |
TGFβ | 2 | 210 | 210 |
HER2 | 3 | 509 | 15 |
ERBB4 | 3 | 490 | 486 |
CASP8 | 2 | 263 | 203 |
P53 | 2 | 467 | 203 |
PTEN | 3 | 260 | 70 |
VDR | 3 | 477 | 497 |
ATM | 3 | 298 | 248 |
BRCA1 | 3 | 259 | – |
MTHFR | 2 | 378 | 306 |
DNMT3 | 2 | 172 | 138 |
ERα | 2 | 169 | 157 |